Health Care·Life Sciences Tools & Services·$2.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.41 | N/A | -14.85% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.41 | N/A | -14.85% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about market conditions impacting performance. They remain committed to their strategic goals.
Management acknowledged challenges in the current market environment.
They emphasized a focus on long-term growth despite short-term setbacks.
The earnings report indicates that 10X Genomics is facing challenges, particularly reflected in the EPS miss. The stock reacted slightly down by 0.02%, suggesting that investors are cautious. Without revenue figures or guidance, uncertainty remains about the company's near-term prospects.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CADENCE DESIGN SYS I
Feb 12, 2024